InspireMD: C-Guardians 30-day results abstract accepted for VIVA23 presentation

InspireMD, Inc.

Abstract of 30-day results from C-Guardians IDE trial accepted as late-breaking presentation at VIVA23 (Oct 30-Nov 2, Las Vegas) on Nov 1, 2023, by Dr. Chris Metzger.
Trial enrolled 316 patients across 25 U.S. and European sites; includes symptomatic and asymptomatic carotid artery stenosis patients.
Primary endpoint: composite of death, all stroke, MI through 30 days and ipsilateral stroke 31-365 days; performance goal: upper bound 95% CI <11.6%.
CEO expects one-year data in H2 2024; if positive, may support PMA and potential U.S. launch of CGuard Prime EPS in H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.